SCHEMBL4616896

SCHEMBL4616896

COc1ccc(OC)c(CCNS(=O)(=O)c2cc(S(=O)(=O)c3ccc(Cl)cc3)ccc2C)c1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SFRP1 Q8N474 2/20 0.52
ALDH1A1 P00352 5/20 0.49
SMN1; SMN2 Q16637 3/20 0.49
USP2 O75604 1/20 0.49
CYP1A2 P05177 1/20 0.49
POLB P06746 1/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2D6 P10635 1/20 0.49
CYP2C9 P11712 1/20 0.49
HPGD P15428 1/20 0.49
TSHR P16473 1/20 0.49
CYP2C19 P33261 1/20 0.49
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
MAPT P10636 1/20 0.47
IDH1 O75874 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
LMNA P02545 2/20 0.44
HTT P42858 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4616168 0.92 SFRP1 (0.54) SFRP1ALDH1A1SMN1; SMN2CYP1A2CYP3A4
SCHEMBL6103373 0.91 SFRP1 (0.64) SFRP1ALDH1A1SMN1; SMN2CYP1A2POLB
SCHEMBL6103669 0.90 MAPT (0.52) SFRP1ALDH1A1SMN1; SMN2USP2POLB
SCHEMBL4619239 0.89 SFRP1 (0.51) SFRP1ALDH1A1SMN1; SMN2USP2CYP1A2
SCHEMBL4619170 0.88 SFRP1 (0.59) SFRP1ALDH1A1SMN1; SMN2USP2CYP1A2
SCHEMBL4617469 0.85 SFRP1 (0.65) SFRP1ALDH1A1SMN1; SMN2POLBMEN1
SCHEMBL4619624 0.84 SFRP1 (0.52) SFRP1ALDH1A1SMN1; SMN2USP2CYP1A2
SCHEMBL6101030 0.84 SFRP1 (0.66) SFRP1ALDH1A1SMN1; SMN2POLBMAPT
SCHEMBL6103073 0.83 SFRP1 (0.61) SFRP1ALDH1A1SMN1; SMN2POLBMEN1
SCHEMBL4618307 0.83 SFRP1 (0.64) SFRP1ALDH1A1SMN1; SMN2POLBIDH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060276464-A1 Diarylsulfone sulfonamides and use thereof WYETH (US) 2006-12-07 US claimed
EP-1879859-A2 DIARYLSULFONE SULFONAMIDES AND USE THEROF Wyeth a Corporation of the State of Delaware (US) 2008-01-23 EP disclosed
US-20060276464-A1 Diarylsulfone sulfonamides and use thereof WYETH (US) 2006-12-07 US disclosed
WO-2006124875-A2 DIARYLSULFONE SULFONAMIDES AND USE THEROF WYETH (US) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276464-A1 Diarylsulfone sulfonamides and use thereof SFRP1, SOS1, FZD7 SFRP1 1/4885ALDH1A1 1865/4885SMN1; SMN2 2404/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.